The lab recieved a new R21 award from the NCI entitled "Circulating HPV DNA as a Prediagnostic Marker of Oropharyngeal Cancer". This grant, done in collaboration with... Read more about Lab Recieves New NIH/NCI R21
Good news was recieved that the lab will be the recipient of a new NIH R03 grant! The research will study a non-invasive liquid biopsy using detection of cell free DNA to determine how the...Read more about Lab awarded new NIH/ NIDCR R03 grant
What happens to ctHPVDNA immediately after surgery for an HPV-associated cancer?
HPV+OPSCC is increasing at epidemic proportions and is commonly treated with transoral robotic surgery(TORS). A new manuscript published by the Faden Lab describes results from a prospective study examining the early clearance kinetics of ctHPVDNA following TORS. Using frequent blood draws immediately after surgery they found that ctHPVDNA levels drop rapidly and clear within hours in patients who lack risk factors for residual disease (RD),...
Two new members joined the Faden lab at the start of 2022.
Dipon Das, PhD received his PhD in cancer biology from KIIT University, India where he studied DNA damage/repair pathways. He completed post-doctoral training at Philips Institute for Oral Health Research, Virginia Commonwealth University, Virginia, USA. His postdoctoral training focused on identifying the host factors that are essential for the Human Papillomavirus (HPV) replication in cervical and head & neck cancers and delineating their mechanism of action. Prior to joining the Faden Lab as a Staff...
Dr. Faden's point-of-care HPV vaccination program was highlighted as one of Boston Medical Center's exceptional programs. The initiative aims to understand HPV vaccine hesitancy, increase vaccination rates and ultimately, prevent the development of HPV-associated head and neck cancers later in life. All patients who visit the Otolaryngology-Head and Neck Surgery Department are asked to complete a survey to assess their knowledge about HPV, the HPV vaccine, and the association between HPV and head and neck cancer. If they indicate interest, patients are...
The incidence of HPV related head and neck cancers (HPV+ HNC) is increasing significantly in the United States. At the same time, we are now seeing patients present with, or develop, multiple HPV+ HNCs, which previously was not a clinical scenario that was thought to occur. This year The Faden Lab, along with colleagues at the University of Pittsburgh, Vanderbilt and the National Cancer Institute ...
As described in a new manuscript published in the journal Cancers, 26% of sinonasal squamous cell carcinomas have detectable HPV. Interestingly, HPV prevalence was higher in subsites with high exposure to secretion flow compared to low exposure subsites and HPV prevalence followed the global distribution of HPV+ oropharyngeal squamous cell carcinoma. This manuscript is the largest analysis of HPV in...